COPD

Teva's generic Advair may sit 'til 2018

The generics maker says it may take five years for its iteration of the GSK asthma/COPD brand to hit the market.

GSK inhaler contender faces FDA panel Tuesday

By

The experimental LAMA/LABA combination could shake up the category.

Business briefs: Actavis, Bayer, Oramed, Elan

Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M

GSK adds competitor to COPD market

By

The FDA approved the Breo/Ellipta combo, but analysts are wary about its potential to go beyond the COPD indication in the US.

Business Briefs: Manhattan Research, KPMG, Scioderm and GSK

Health-seeking consumers continue social-media push; Scioderm scores FDA's "Breakthrough" designation for bullosa agent; and GSK files NDA for airway treatment.

GSK's Advair successor gets adcomm thumbs-up

By

An FDA advisory committee recommended approving Breo for COPD. Assuming it goes through, GSK will have to woo payers to upgrade from the older drug.

Boehringer Ingelheim contest seeks COPD songs

Boehringer Ingelheim contest seeks COPD songs

By

Boehringer Ingelheim is partnering with the Country Music Association for a Tune Up For COPD Songwriting Competition featuring country music stars Billy Ray Cyrus and Patty Loveless.

AZ rebranded effort: 'Rethink COPD'

By

AstraZeneca is rolling out an unbranded COPD education campaign featuring comedian and actor Robert Klein. The campaign, dubbed Rethink COPD, is aimed at getting sufferers to consider their options with respect to diet, exercise and, of course, medication.

Email Newsletters